Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

GPCR

Structure Therapeutics Inc ADR

May 03 • 04:00PM ET

39.29

Dollar change +0.30
Percentage change 0.77	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.51	Insider Own	11.06%	Shs Outstand	46.41M	Perf Week	0.90%
Market Cap	1.83B	Forward P/E	-	EPS next Y	-0.99	Insider Trans	0.00%	Shs Float	41.44M	Perf Month	-0.03%
Income	-89.51M	PEG	-	EPS next Q	-0.21	Inst Own	81.83%	Short Float	9.93%	Perf Quarter	-10.26%
Sales	0.00M	P/S	-	EPS this Y	-17.46%	Inst Trans	-	Short Ratio	7.05	Perf Half Y	-46.81%
Book/sh	9.76	P/B	4.03	EPS next Y	-4.50%	ROA	-30.87%	Short Interest	4.11M	Perf Year	62.02%
Cash/sh	10.03	P/C	3.92	EPS next 5Y	-	ROE	-33.29%	52W Range	21.79 - 75.02	Perf YTD	-3.61%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-19.59%	52W High	-47.62%	Beta	-3.67
Dividend TTM	-	Quick Ratio	19.14	Sales past 5Y	0.00%	Gross Margin	-	52W Low	80.31%	ATR (14)	2.05
Dividend Ex-Date	-	Current Ratio	19.14	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	51.56	Volatility	4.60% 5.27%
Employees	93	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	80.50
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-64.07%	Payout	-	Rel Volume	0.60	Prev Close	38.99
Sales Surprise	-	EPS Surprise	19.35%	Sales Q/Q	-	Earnings	Mar 08 BMO	Avg Volume	583.94K	Price	39.29
SMA20	1.32%	SMA50	-0.11%	SMA200	-10.34%	Trades		Volume	349,845	Change	0.77%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-24	Initiated	Cantor Fitzgerald	Overweight	$65
Oct-19-23	Initiated	JMP Securities	Mkt Outperform	$90
Jul-27-23	Initiated	Piper Sandler	Overweight	$58
May-25-23	Resumed	Jefferies	Buy	$34 → $41
Feb-28-23	Initiated	SVB Securities	Outperform	$33
Feb-28-23	Initiated	Jefferies	Buy	$34
Feb-28-23	Initiated	Guggenheim	Buy	$50
Feb-28-23	Initiated	BMO Capital Markets	Outperform	$40

Apr-24-24 06:33AM	3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains (InvestorPlace)
Mar-30-24 09:37AM	7 Small-Cap Stocks that Wall Street Loves for Good Reason (InvestorPlace)
Mar-15-24 10:53AM	GPCR Stock Earnings: Structure Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
Mar-08-24 04:05PM	Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference (GlobeNewswire)
08:30AM	Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
05:24AM	Loading…
Jan-22-24 05:24AM	Here's Why Structure Therapeutics (GPCR) Fell in Q4 (Insider Monkey)
Dec-25-23 07:45AM	Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now (Motley Fool)
Dec-22-23 04:21PM	7 Small-Cap Stocks That Wall Street Loves for Good Reason (InvestorPlace) +7.85%
Dec-18-23 04:06PM	Structure Plummets 43% After Trailing Lilly In Obesity Treatment (Investor's Business Daily) -42.82%
01:03PM	Another Drugmaker Hits Rocks Seeking a Weight-Loss Pill (The Wall Street Journal)
11:29AM	New Shakeup Hits Obesity Pills. Structure Rolls Out Disappointing Data. (Barrons.com)
09:22AM	Structure Stock Takes A Brutal Beating After Obesity Drug Trails Lilly's Leader (Investor's Business Daily)
07:30AM	Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study (GlobeNewswire)
07:30AM	Structure Therapeutic obesity pill shows promise in mid-stage trial (Reuters)
06:23AM	Structure shares sink as obesity pill misses expectations in small study (BioPharma Dive)
12:26PM	Loading…
Dec-11-23 12:26PM	3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023 (InvestorPlace)
Nov-29-23 02:28PM	If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names (InvestorPlace)
02:30AM	11 Best Young Stocks to Buy and Hold For 20 Years (Insider Monkey)
Nov-27-23 09:50AM	11 Best Upside Stocks To Buy Right Now (Insider Monkey)
Nov-26-23 04:44PM	2 Biotech Stocks That Could Soar in December (Motley Fool)
Nov-14-23 04:10PM	Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Nov-03-23 05:20AM	Should You Still Buy the Nasdaq's Best-Performing October Stocks? (Motley Fool)
Oct-19-23 08:45AM	Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders (PR Newswire)
Oct-06-23 08:45AM	Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why (Zacks)
Oct-02-23 03:48PM	Why Shares of Structure Therapeutics Are Up Monday (Motley Fool) +12.26%
Sep-29-23 04:04PM	Structure Soars 35% As Newcomer Takes On Behemoths Lilly, Novo In Obesity Treatment (Investor's Business Daily) +34.56%
12:50PM	Why Shares of Structure Therapeutics Are Soaring on Friday (Motley Fool)
11:19AM	Structure Stock Soars. Its Obesity Pill Could Challenge Lilly, Novo. (Barrons.com)
10:24AM	Upstart Weight-Loss Drugmaker Jumps 75% on Strong Test Results (Bloomberg)
09:34AM	Newcomer Structure Throws Down The Gauntlet In Obesity Treatment -- Shares Soar 66% (Investor's Business Daily)
07:32AM	Loading…
07:32AM	Structure Therapeutics Announces $300 Million Private Placement Equity Financing (GlobeNewswire)
07:30AM	Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update (GlobeNewswire)
Aug-10-23 04:05PM	Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Aug-03-23 05:32PM	Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors (GlobeNewswire)
Jul-16-23 07:00AM	Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In. (The Wall Street Journal)
Jun-27-23 02:10PM	Eli Lilly, Pfizer, and Others Are Working on Weight-Loss Pills. What to Know. (Barrons.com) +8.16%
01:35PM	Lilly, Pfizer and Others Are Working on Obesity Pills. What to Know. (Barrons.com)
08:12AM	Pfizer Makes a Call on Obesity Pill. Investors Arent Happy. (Barrons.com)
Jun-26-23 09:05PM	Why Shares of Structure Therapeutics Rose Monday (Motley Fool) +18.35%
Jun-16-23 08:00AM	This Biotech Is Developing The Next Ozempic. Should You Buy It? (Motley Fool)
Jun-13-23 06:10AM	Institutional investors own a significant stake of 45% in Structure Therapeutics Inc. (NASDAQ:GPCR) (Simply Wall St.)
Jun-12-23 10:15AM	Buying Shares of These 2 Biotech Stocks Could Be a Brilliant Move in 5 Years (Motley Fool)
Jun-07-23 08:30AM	Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions (GlobeNewswire)
May-31-23 04:30PM	Structure Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-25-23 04:30PM	Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity (GlobeNewswire) +7.94%
May-18-23 04:30PM	Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference (GlobeNewswire)
May-11-23 04:30PM	Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-03-23 06:59AM	Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-30-23 04:30PM	Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights (GlobeNewswire)
Feb-07-23 04:00PM	Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional American Depositary Shares (GlobeNewswire)
Feb-06-23 03:17PM	The Funded: A solar industry company is on deck to complete the 1st major Bay Area tech IPO in more than a year (American City Business Journals)

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in South San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GPCR

Structure Therapeutics Inc ADR

Upgrade your FINVIZ experience